APRIL 16-18, 2019


The 6th Annual Translational Microbiome Conference is Coming Back to Boston in April 2020. 

Please check back in the coming weeks for additional details.

Expert Panel Discussions to be Highlight of Agenda at the 3rd Annual Translational Microbiome Conference

Minneapolis, MN – February 15, 2017 – Arrowhead Publishers is pleased to announce that a variety of expert panel discussions have been announced for its upcoming 3rd Annual Translational Microbiome Conference. This event, which will take place April 11-13, 2017 in Boston, MA, will unite presenters and attendees from academia, industry, and the government to provide a multi-stakeholder perspective on the latest trends and developments in the microbiome space. For more information, visit: http://www.microbiomeconference.com.

The CEO of CosmosID Inc. Manoj Dadlani will lead the panel on bioinformatics tools for clinical applications in metagenomics, as well as challenges to overcome in the complex clinical and regulatory environments. Panelists will also discuss the dire need for robust bioinformatics tools that can address the complex clinical and regulatory environments.

Co-founder and CEO of Whole Biome, Dr. Colleen Cultcliffe, will be leading a panel discussion on the microbiome and its growing presence in the media. As new therapeutics are being developed, the microbiome industry must find ways to overcome the hype and unrealistic timelines that can be expected by the general public.

Mohan S. Iyer, CBO at Second Genome, will be moderating the panel on pharma companies working in the microbiome industry. He and the panelists will discuss the latest partnerships between the microbiome industry and pharma, and the deals outlook for 2017.

The “Strategies and Risks for Developing Comprehensive Patent and Licensing Strategies” panel will be led by Greg Sieczkiewicz, Managing Director at MPM Capital. This panel will analyze the various challenges and opportunities that organizations will experience when developing a patent portfolio in the microbiome therapeutics industry. They will also discuss what is necessary from a licensing perspective in order to create a successful pharma-biotech relationship.

Director of Research and Development of Reckitt Benckiser, Joe Rubino, will moderate the panel discussion “Time to Put the Hygiene Hypothesis to Rest?”

JP Benya, Vice President Commercial of Assembly Biosciences will lead the panel discussion on commercial challenges and opportunities in the microbiome-based therapeutics industry. By focusing on critical factors to consider when launching a MBT including regulatory considerations, customer expectations, and messaging implications, this panel will provide expert insight into the future of microbiome-based therapeutics.

Arrowhead Publishers’ 3rd Annual Translational Microbiome Conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others), attendees will have the opportunity to hear the leading companies discuss integral components of successful businesses. For more information, visit: http://www.microbiomeconference.com/brochure.

For more information, please contact:

John Waslif: Managing Director

Arrowhead Publishers

866-945-0263 ext 700

This email address is being protected from spambots. You need JavaScript enabled to view it.

Rachel Donlon: Marketing Associate

Arrowhead Publishers

866-945-0263 ext 701

This email address is being protected from spambots. You need JavaScript enabled to view it.


The Microbiome-Vaccine Summit: Microbiome-Mediated Immunity and the Future of Vaccines

Dates and Location: September 2019 | London, United Kingdom

Microbes in the gut have been found to exert profound control over the immune system. The role of the microbiome in modulating the immune response has already been substantially researched with numerous correlations between the microbiome’s immune effects and disease hypothesized and being explored. One exciting area of inquiry is the potential for the microbiome to play a substantial role in vaccine response. This area of exploration includes:

♦ Its potential to change how patients respond to checkpoint inhibition therapy for metastatic melanoma
♦ Correlations between the efficacy of the rotavirus and geographic differences in the gut biome
♦ How the antibiotic-mediated dysbiotic gut microbiome may actually mount a strong immune response to the seasonal flu vaccine
♦ And the gut-lung axis, or the role of the microbiome in the meteoric rise of asthma
♦ And even the possibility of explaining why some children experience adverse reactions to vaccinations, and why our current vaccine protocol starting within 12 hours of birth does not properly factor gut microbiota as crucial to immune response.

An extension of the highly successful Arrowhead Translational Microbiome Conference held every April in Boston, join us for this first event in our Translational Microbiome Spotlight series, where we bring together industry and academic experts considering the interface between the microbiome and vaccines in a one day, highly interactive roundtable forum.

CLICK HERE to request more information. If you are interested in speaking or sponsorship opportunities, please email This email address is being protected from spambots. You need JavaScript enabled to view it..